

MERCK'S COMMITMENT TO INNOVATION



Driving Innovation

to discover and develop new ways to prevent and treat diseases

Monitoring Trends

in AMR (antimicrobial resistance) through large and long-running surveillance studies



Advancing Responsible Use

of antimicrobials in humans and animals through the support of evidence-based antimicrobial stewardship (AMS) policies and activities

Advocating for Policy Changes

to enable appropriate patient access and sustainable investment into the development of novel vaccines and medication



MERCK'S CONTINUED COMMITMENT TO INNOVATION:

- ongoing clinical trials addressing infections and other diseases
- development of novel medication, including antibiotics
- funding investigator-initiated studies, including antimicrobial stewardship programs across the globe
- initiation of one of the world's largest AMR surveillance studies, in which 63 countries around the world have participated

FOR MORE THAN 100 YEARS

Merck has contributed to the discovery and development of novel medicines and vaccines to combat diseases

1930-1939

Merck Research Laboratories played a **central role in the development** of the first antimicrobials (sulfas).

1940-1949

Merck, in collaboration with Rutgers University, developed one of **the first methods for mass production of penicillin**. Merck also helped to develop the first antibiotic effective against tuberculosis.

1950-1969

Developed **multiple novel methods** to prevent diseases, including pediatric vaccines

1970-2020

Developed **multiple novel medications**, including vaccines, antibiotics and antifungals

Today

Continues to **invest in R&D and markets a number of products** to treat or prevent disease